Cat. No. 3967
Chemical Name: 2-Chloro-N-[1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-6H-thieno[2,3-b]pyrrole-5-carboxamide
Biological ActivityAllosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775. PMID: 17016495.
Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239. PMID: 17934512.
If you know of a relevant citation for this product please let us know.
Keywords: GPi 688, supplier, GPi688, glycogen, phosphorylase, inhibitor, hyperglycaemia, hyperglycemia, inhibits, astrazeneca
Find multiple products by catalog number
New Products in this Area
Geranylgeranyltransferase I (GGTase I) inhibitorEntacapone
Potent COMT inhibitor; blocks α-synuclein aggregation
Meet your representative
October 15, 2013